143 related articles for article (PubMed ID: 36249041)
1. The risk factors and early predictive model of hematotoxicity after CD19 chimeric antigen receptor T cell therapy.
Wang Y; Song Z; Geng Y; Gao L; Xu L; Tang G; Ni X; Chen L; Chen J; Wang T; Fu W; Feng D; Yu X; Wang L; Yang J
Front Oncol; 2022; 12():987965. PubMed ID: 36249041
[TBL] [Abstract][Full Text] [Related]
2. Clinical Impact of Cytokine Release Syndrome on Prolonged Hematotoxicity after Chimeric Antigen Receptor T Cell Therapy: KyoTox A-Score, a Novel Prediction Model.
Nakamura N; Jo T; Arai Y; Kitawaki T; Nishikori M; Mizumoto C; Kanda J; Yamashita K; Nagao M; Takaori-Kondo A
Transplant Cell Ther; 2024 Apr; 30(4):404-414. PubMed ID: 38281589
[TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness of Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed or Refractory Large B Cell Lymphoma: No Impact of Site of Care.
Cummings Joyner AK; Snider JT; Wade SW; Wang ST; Buessing MG; Johnson S; Gergis U
Adv Ther; 2022 Aug; 39(8):3560-3577. PubMed ID: 35689726
[TBL] [Abstract][Full Text] [Related]
4. Investigation of the risk factors to predict cytokine release syndrome in relapsed or refractory B-cell acute lymphoblastic leukemia patients receiving IL-6 knocking down anti-CD19 chimeric antigen receptor T-cell therapy.
Gong WJ; Qiu Y; Li MH; Chen LY; Li YY; Yu JQ; Kang LQ; Sun AN; Wu DP; Yu L; Xue SL
Front Immunol; 2022; 13():922212. PubMed ID: 36105799
[TBL] [Abstract][Full Text] [Related]
5. CD4
Pan Y; Wang H; An F; Wu F; Tao Q; Li Y; Ruan Y; Zhai Z
Int Immunopharmacol; 2021 Jul; 96():107742. PubMed ID: 33984717
[TBL] [Abstract][Full Text] [Related]
6. CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma.
Rejeski K; Perez A; Sesques P; Hoster E; Berger C; Jentzsch L; Mougiakakos D; Frölich L; Ackermann J; Bücklein V; Blumenberg V; Schmidt C; Jallades L; Fehse B; Faul C; Karschnia P; Weigert O; Dreyling M; Locke FL; von Bergwelt-Baildon M; Mackensen A; Bethge W; Ayuk F; Bachy E; Salles G; Jain MD; Subklewe M
Blood; 2021 Dec; 138(24):2499-2513. PubMed ID: 34166502
[TBL] [Abstract][Full Text] [Related]
7. Third-generation CD28/4-1BB chimeric antigen receptor T cells for chemotherapy relapsed or refractory acute lymphoblastic leukaemia: a non-randomised, open-label phase I trial protocol.
Tang XY; Sun Y; Zhang A; Hu GL; Cao W; Wang DH; Zhang B; Chen H
BMJ Open; 2016 Dec; 6(12):e013904. PubMed ID: 28039295
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia.
Gu R; Liu F; Zou D; Xu Y; Lu Y; Liu B; Liu W; Chen X; Liu K; Guo Y; Gong X; Lv R; Chen X; Zhou C; Zhong M; Wang H; Wei H; Mi Y; Qiu L; Lv L; Wang M; Wang Y; Zhu X; Wang J
J Hematol Oncol; 2020 Sep; 13(1):122. PubMed ID: 32894185
[TBL] [Abstract][Full Text] [Related]
9. Identification of the Predictive Models for the Treatment Response of Refractory/Relapsed B-Cell ALL Patients Receiving CAR-T Therapy.
Gu J; Liu S; Cui W; Dai H; Cui Q; Yin J; Li Z; Kang L; Qiu H; Han Y; Miao M; Chen S; Xue S; Wang Y; Jin Z; Zhu X; Yu L; Wu D; Tang X
Front Immunol; 2022; 13():858590. PubMed ID: 35371098
[TBL] [Abstract][Full Text] [Related]
10. [Safety and efficacy of CD19-targeted CAR-T cells in 14 patients with refractory/relapsed Philadelphia chromosome-positive acute B-precursor lymphoblastic leukemia].
He CX; Xue L; Qiang P; Xu H; Zhang XH; Liu X; Zhu WW; Cai XY; Liu HL; Sun ZM; Wang XB
Zhonghua Xue Ye Xue Za Zhi; 2020 Jun; 41(6):490-494. PubMed ID: 32654463
[No Abstract] [Full Text] [Related]
11. Cytokine Release Syndrome Grade as a Predictive Marker for Infections in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Treated With Chimeric Antigen Receptor T Cells.
Park JH; Romero FA; Taur Y; Sadelain M; Brentjens RJ; Hohl TM; Seo SK
Clin Infect Dis; 2018 Aug; 67(4):533-540. PubMed ID: 29481659
[TBL] [Abstract][Full Text] [Related]
12. Predictive role of endothelial cell activation in cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukaemia.
Hong F; Shi M; Cao J; Wang Y; Gong Y; Gao H; Li Z; Zheng J; Zeng L; He A; Xu K
J Cell Mol Med; 2021 Dec; 25(24):11063-11074. PubMed ID: 34734474
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy and safety of CD19 chimeric antigen receptor T cells for the treatment of 22 patients with B-cell lymphoma].
Xiao X; Jiang YY; Cao YQ; Li Q; Jin X; Meng JX; Sui T; Li YM; Zhao MF
Zhonghua Xue Ye Xue Za Zhi; 2019 Apr; 40(4):276-280. PubMed ID: 31104437
[No Abstract] [Full Text] [Related]
14. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
15. Axicabtagene Ciloleucel: Clinical Data for the Use of CAR T-cell Therapy in Relapsed and Refractory Large B-cell Lymphoma.
Halford Z; Anderson MK; Bennett LL
Ann Pharmacother; 2021 Mar; 55(3):390-405. PubMed ID: 32698673
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of CD19 CAR-T cell therapy for patients with B cell acute lymphoblastic leukemia involving extramedullary relapse.
Huang L; Zhang M; Wei G; Zhao H; Hu Y; Huang H
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 51(2):151-159. PubMed ID: 36161297
[TBL] [Abstract][Full Text] [Related]
17. Impact of Consolidative Unrelated Cord Blood Transplantation on Clinical Outcomes of Patients With Relapsed/Refractory Acute B Lymphoblastic Leukemia Entering Remission Following CD19 Chimeric Antigen Receptor T Cells.
Xu Q; Xue L; An F; Xu H; Wang L; Geng L; Zhang X; Song K; Yao W; Wan X; Tong J; Liu H; Liu X; Zhu X; Zhai Z; Sun Z; Wang X
Front Immunol; 2022; 13():879030. PubMed ID: 35558072
[TBL] [Abstract][Full Text] [Related]
18. Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment.
Yan Z; Zhang H; Cao J; Zhang C; Liu H; Huang H; Cheng H; Qiao J; Wang Y; Wang Y; Gao L; Shi M; Sang W; Zhu F; Li D; Sun H; Wu Q; Qi Y; Li H; Wang X; Li Z; Liu H; Zheng J; Qian W; Zhang X; Xu K
Front Immunol; 2021; 12():611366. PubMed ID: 33708205
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of CD19 chimeric antigen receptor T cells in the treatment of 11 patients with relapsed/refractory B-cell lymphoma: a single-center study.
Huang C; Wu L; Liu R; Li W; Li Z; Li J; Liu L; Shan B
Ann Transl Med; 2020 Sep; 8(17):1048. PubMed ID: 33145267
[TBL] [Abstract][Full Text] [Related]
20. Humanized Anti-CD19 CAR-T Cell Therapy and Sequential Allogeneic Hematopoietic Stem Cell Transplantation Achieved Long-Term Survival in Refractory and Relapsed B Lymphocytic Leukemia: A Retrospective Study of CAR-T Cell Therapy.
Chen W; Ma Y; Shen Z; Chen H; Ma R; Yan D; Shi M; Wang X; Song X; Sun C; Cao J; Cheng H; Zhu F; Sun H; Li D; Li Z; Zheng J; Xu K; Sang W
Front Immunol; 2021; 12():755549. PubMed ID: 34777367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
